Brokerages Set Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) Target Price at $42.00
Shares of Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) have received a consensus recommendation of “Buy” from the twelve research firms that are currently covering the firm. Three investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $42.00.
A number of equities research analysts have recently commented on the company. Maxim Group raised their price target on Zeltiq Aesthetics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Stifel Nicolaus increased their price objective on Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, September 21st. Zacks Investment Research upgraded Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a report on Saturday, July 23rd. Brean Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Zeltiq Aesthetics in a report on Tuesday, June 21st. Finally, Leerink Swann reiterated an “outperform” rating and set a $48.00 price objective on shares of Zeltiq Aesthetics in a report on Thursday, August 25th.
Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 40.22 on Thursday. The stock’s 50 day moving average price is $38.74 and its 200-day moving average price is $31.88. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of 60.48 and a beta of 0.79. Zeltiq Aesthetics has a one year low of $18.41 and a one year high of $41.43.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. The business had revenue of $89.50 million for the quarter, compared to analyst estimates of $79.68 million. Zeltiq Aesthetics had a negative return on equity of 9.90% and a net margin of 9.54%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.03 EPS. On average, equities research analysts expect that Zeltiq Aesthetics will post ($0.13) EPS for the current fiscal year.
In related news, Director Andrew N. Schiff sold 500,000 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $36.39, for a total transaction of $18,195,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kevin C. Oboyle sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $40.08, for a total value of $300,600.00. Following the transaction, the director now directly owns 19,485 shares in the company, valued at $780,958.80. The disclosure for this sale can be found here. Corporate insiders own 15.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. PineBridge Investments L.P. raised its position in Zeltiq Aesthetics by 4.9% in the second quarter. PineBridge Investments L.P. now owns 4,103 shares of the company’s stock worth $112,000 after buying an additional 193 shares during the last quarter. Teacher Retirement System of Texas raised its position in Zeltiq Aesthetics by 26.9% in the second quarter. Teacher Retirement System of Texas now owns 4,884 shares of the company’s stock worth $133,000 after buying an additional 1,036 shares during the last quarter. Legal & General Group Plc raised its position in Zeltiq Aesthetics by 1.7% in the first quarter. Legal & General Group Plc now owns 4,963 shares of the company’s stock worth $134,000 after buying an additional 83 shares during the last quarter. Mason Street Advisors LLC acquired a new position in Zeltiq Aesthetics during the second quarter worth $173,000. Finally, Calamos Wealth Management LLC acquired a new position in Zeltiq Aesthetics during the second quarter worth $200,000.
Zeltiq Aesthetics Company Profile
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.